MedTrace Logo

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

NCT02887495 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-07-27

No results posted yet for this study

Summary

The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.

Conditions

  • Scleroderma

Sponsors & Collaborators

  • George Washington University

    lead OTHER

Principal Investigators

  • Victoria K Shanmugam, MD · The George Washington University

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2022-02-02
Completion
2022-02-02

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02887495 on ClinicalTrials.gov